Disclosed in the present invention are a composition containing lutein/lutein ester and applications thereof. Components of the composition containing lutein/lutein ester comprise lutein/lutein ester, .beta.-carotene and a pharmaceutically acceptable carrier. The weight ratio of lutein/lutein ester to .beta.-carotene is 1:0.1-100. In the present invention, by cooperatively using lutein/lutein ester and .beta.-carotene and using auxiliary natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through the oral cavity, has fast effectiveness and small first-pass effect, reduces damage of gastric acid to lutein/lutein ester, has high bioavailability, and has the characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By eating the product, visual power can be obviously enhanced, the ocular blood flow is increased, and eye muscle fatigue is alleviated, and accordingly the morbidities of cataract, senile niacula lutea retinae lesion and adolescent myopia are reduced.

SinoNutraceutical Co., Ltd.

Composition containing lutein/lutein ester and applications thereof

This invention relates to an optical lenses, which includes a lens substrate, a multi-layers film is set on one side of the lens substrate to block partial blue light and infrared light. The multi-layers film is formed by interactive stacking a plurality of layers of a low refractive index film (such as silicon dioxide film, the mix material film which is composed of silicon dioxide and alumina or the mix material film which is composed of silicon dioxide and silicon oxide) and a high refractive index film (such as zirconium dioxide film, trititanium pentoxide film, titanium dioxide film, tantalum pentoxide film or the mix material which is composed of zirconium dioxide and titanium dioxide), and each layer of film is used a specific thickness. So that, the optical lens can produce the effect of blocking partial blue light and infrared light without overly increased in color, allowing the user's eyes to keep cool due to partial infrared light blocking. Moreover, the optical lens can also reduce the user's eyes produce age related macular degeneration or cataract to achieve the effect of reduce eye fatigue and prolong vision view due to partial blue light blocking.

ONELENSOLUTION OPTICAL TECHNOLOGY SDN BHD

Optical lenses

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

cataract/únava

Composition containing lutein/lutein ester and applications thereof

Optical lenses

Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors

Nejúplnější databáze léčivých bylin podložená vědou